INTRODUCTION: Delayed haemolytic anaemia is one of the more frequent events after treatment with intravenous artesunate in patients with severe malaria. Little is known about its frequency and the outcomes of patients with this condition. METHODS: A retrospective study was conducted to describe the incidence of delayed haemolysis in a cohort of patients with severe malaria by Plasmodium falciparum treated with artesunate between August 2013 and July 2015. RESULTS: The study included 52 patients with malaria due to Plasmodium falciparum, with 21 having severe malaria. The majority were male (66.7%), ...
BACKGROUND: Delayed haemolysis is a frequent adverse event after treatment with artesunate (AS). Rem...
We report a case of post-artesunate delayed haemolysis (PADH) in severe Plasmodium falciparum malari...
A documented side-effect of artemisinin therapy is post-artemisinin delayed hemolysis (PADH), primar...
INTRODUCTION: Delayed haemolytic anaemia is one of the more frequent events after t...
Artesunate is the drug of choice for treating patients with severe malaria. Post-artesunate delayed ...
Abstract Parenteral artesunate has been shown to be a superior treatment option compared to parenter...
International audienceBackground: Parenteral artesunate is recommended as first-line therapy for sev...
Artesunate is the most effective treatment for severe malaria. However, delayed-onset hemolytic anem...
As a result of a huge effort of the international community, the burden of malaria dropped impressiv...
SummaryBackgroundArtemisinin derivatives are the mainstay of antimalarial treatment, both for uncomp...
Episodes of delayed hemolysis 2-6 weeks after treatment of severe malaria with intravenous artesunat...
Episodes of delayed hemolysis 2–6 weeks after treatment of severe malaria with intravenous artesunat...
Background Parenteral artesunate is the treatment of choice for severe malaria. Recently, haemolytic...
International audienceBACKGROUND: In sub-Saharan Africa, artemisinin-based combination therapy (ACT)...
International audienceWe read with interest the article by Rehman et al. on post-artesunate hemolysi...
BACKGROUND: Delayed haemolysis is a frequent adverse event after treatment with artesunate (AS). Rem...
We report a case of post-artesunate delayed haemolysis (PADH) in severe Plasmodium falciparum malari...
A documented side-effect of artemisinin therapy is post-artemisinin delayed hemolysis (PADH), primar...
INTRODUCTION: Delayed haemolytic anaemia is one of the more frequent events after t...
Artesunate is the drug of choice for treating patients with severe malaria. Post-artesunate delayed ...
Abstract Parenteral artesunate has been shown to be a superior treatment option compared to parenter...
International audienceBackground: Parenteral artesunate is recommended as first-line therapy for sev...
Artesunate is the most effective treatment for severe malaria. However, delayed-onset hemolytic anem...
As a result of a huge effort of the international community, the burden of malaria dropped impressiv...
SummaryBackgroundArtemisinin derivatives are the mainstay of antimalarial treatment, both for uncomp...
Episodes of delayed hemolysis 2-6 weeks after treatment of severe malaria with intravenous artesunat...
Episodes of delayed hemolysis 2–6 weeks after treatment of severe malaria with intravenous artesunat...
Background Parenteral artesunate is the treatment of choice for severe malaria. Recently, haemolytic...
International audienceBACKGROUND: In sub-Saharan Africa, artemisinin-based combination therapy (ACT)...
International audienceWe read with interest the article by Rehman et al. on post-artesunate hemolysi...
BACKGROUND: Delayed haemolysis is a frequent adverse event after treatment with artesunate (AS). Rem...
We report a case of post-artesunate delayed haemolysis (PADH) in severe Plasmodium falciparum malari...
A documented side-effect of artemisinin therapy is post-artemisinin delayed hemolysis (PADH), primar...